Approved by the Board of Trustees

September 19, 2024

**11**

Board Meeting

September 19, 2024

# ROLL CALL

# PURCHASE RECOMMENDATIONS

Following are purchase recommendations proposed by each university and the System Office. The purchases are to be funded from State appropriations or institutional funds as appropriate. Unless otherwise specified or indicated, purchases are based on the lowest acceptable bid. The vice president/chief financial officer and comptroller has approved all purchases to be funded from State appropriations in accordance with the *Bylaws of the Board of Trustees* and the *General Rules Concerning University Organization and Procedure.*

The Board action recommended in this item complies in all material respects with applicable State and federal laws, University of Illinois *Statutes*, *The General Rules Concerning University Organization and Procedure*, and Board of Trustees policies and directives.

The president of the University of Illinois System concurs.

**PURCHASES RECOMMENDED**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | |  | |
| |  | | --- | | **University of Illinois Chicago** | | | | | |
| 1 | Unit | | UI Hospital and Clinics | |
|  | Item | | Purchase of Specialty Pharmaceuticals Yescarta and Tecartus for UI Hospital and Clinics. For the period of October 1, 2024, to September 30, 2027. | |
|  | Cost | | $7,000,000 (estimated) | |
|  | Vendor | | Cardinal Health Specialty Pharmacy Columbia, Maryland | |
|  |  | | Purchase of specialty pharmaceuticals used in CAR-T (Chimeric Antigen Receptor Therapy), an immunological treatment that uses the body’s own immune system to destroy cancerous cells. These pharmaceuticals (Yescarta and Tecartus) are used as a last option for patients who have failed previous cancer treatment. CAR-T is similar to autologous bone marrow transplant. The patient’s own white blood cells are harvested, then used to engineer and grow the cell product which is shipped back to UI Hospital to be infused to the patient in the bone marrow transplant unit.  The manufacturer of Yescarta and Tecartus has licensed the exclusive distribution rights to Cardinal Health Specialty Pharmacy. These products can only be obtained through Cardinal.  This purchase is exempt from competitive selection procedures in accordance with the Illinois Procurement Code (30ILCS 500/1-13(b-5)).  **Business Enterprise Program (BEP)** goals are not established for contracts that are exempt from the requirements of the Illinois Procurement Code. | |
|  | |  | |  |

|  |  |
| --- | --- |
| **SUMMARY OF PURCHASES** | |
| University of Illinois Chicago | $ 7,000,000 |
| Recommended from Institutional Funds  Grand Total | $ 7,000,000 |
|  |  |